**Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics** This study aims to see how a medicine called benralizumab affects the lungs of people with severe eosinophilic asthma. Asthma is a lung condition that makes it hard to breathe. Eosinophils are a type of white blood cell that can cause asthma symptoms. Participants will receive treatment for 48 weeks and must have ongoing asthma symptoms despite using inhaled corticosteroids (ICS) and a long-acting B2-agonist (LABA), which are common asthma medicines. After treatment, there will be a 4-week follow-up. **Key Points:** - **Duration:** The study lasts for about 1 year, including treatment and follow-up. - **Eligibility:** Adults aged 18-70, diagnosed with asthma, and already on specific asthma treatments. - **Exclusions:** You cannot participate if you smoke, have a history of cancer, or are pregnant. This study might help in understanding how benralizumab can improve asthma symptoms, but make sure you meet the requirements to participate safely.